相关实验视频

Updated: May 12, 2026

Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro

Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro

Published on: July 5, 2017

Endopleura uchi树皮水性提取物的基因毒性和抗增殖性质

Glaucia Cristina de Lima E Souza Mesquita¹, Elkejer Ribeiro Da Cruz^1,2, Dione Silva Corrêa²

¹Laboratory of Genetic Toxicology, Lutheran University of Brazil (ULBRA), Canoas, RS, Brazil.

Journal of toxicology and environmental health. Part A

|April 15, 2024

概括

皮提取物Endopleura uchi表现出细胞毒性和基因毒性作用,可能与其抗瘤特性有关. 然而,它的突变性需要谨慎治疗使用.

科学领域:

植物化学植物化学
毒理学毒理学毒理学
癌症研究癌症研究

背景情况:

皮提取物 Endopleura uchi 传统上用于治疗妇科疾病,糖尿病和脂质失调症,没有科学验证.
乌树皮提取物的安全性,特别是其突变性潜力,仍然没有被描述.

研究的目的:

为了研究E. uchi树皮水性提取物的化学成分.
评估提取物的抗瘤和毒理学参数.

主要方法:

使用色度和色谱方法进行植物化学分析.
通过硫黄胺B (SRB) 试验对四种癌细胞系进行评估的抗增殖活性.
用MTT,彗星,微核和沙门氏菌/微小组测试评估的细胞毒性,基因毒性和变异性.

主要成果:

发现的主要化合物是酸和异基素.
提取物对HT-29 (结肠) 和MCF-7 (乳腺) 癌细胞系表现出显著的抗增殖作用.
在MTT试验中观察到IC50为39.1μg/ml. 在特定的测定和细胞系中检测到基因毒性和突变性活动.

结论:

E. uchi 树皮含有具有细胞毒和基因毒性质的生物活性化合物,可能有助于其抗瘤作用.
鉴定到的基因毒性和致变性活动,需要对E. uchi树皮水性提取物的治疗应用保持谨慎.

关键词:

这是一种抗瘤药物.造成的DNA损伤是DNA损伤.最后一个是 Endopleura Uchi.酸是一种酸.异基氨酸 (ISOQUERCITRIN) 是一种突变性突变性突变性

更多相关视频

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Published on: March 20, 2018

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

相关概念视频

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...